The following is a summary of “Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry,” published in the November 2023 issue of Dermatology by Jin, et al.

There are no well-defined criteria for psoriasis patients exhibiting poor therapeutic responses to multiple biologic agents. For a study, researchers sought to characterize the features associated with developing multiple biologic failure (MBF) compared to those with an excellent clinical response (GR) to the first biologic.

In the prospective cohort analysis, patients from the multicenter CorEvitas Psoriasis Registry who initiated their first biologic between 2015 and 2020 and were followed for at least 24 months were evaluated. Multivariable logistic regression identified sociodemographic, clinical, and patient-reported outcomes that differed between MBF (discontinued two or more biologics of different classes, each used for at least 90 days due to inadequate efficacy) and GR (continued use of the first biologic for at least two years) patients.

A total of 1,039 patients were analyzed (490 GR [47.2%], 65 MBF [6.3%]). Female sex, shorter psoriasis duration, earlier year of biologic initiation, prior nonbiologic systemic therapy use, a history of hyperlipidemia, and Medicaid insurance were significantly associated with MBF, although the latter two variables exhibited wider CIs, indicating a lower level of support. The most observed first-to-second biologic sequence with MBF was tumor necrosis factor-α inhibitor to IL-17 inhibitor use.

Approximately 6% of psoriasis patients met the criteria for MBF. The results identified characteristics associated with MBF that may distinguish patients warranting more frequent follow-up.

Source: jaad.org/article/S0190-9622(23)02393-9/fulltext